Americana Partners LLC Takes Position in Bristol-Myers Squibb (NYSE:BMY)

Americana Partners LLC purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 213,637 shares of the biopharmaceutical company's stock, valued at approximately $12,083,000.

Several other institutional investors have also recently bought and sold shares of BMY. AMF Tjanstepension AB raised its holdings in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company's stock worth $31,618,000 after acquiring an additional 39,419 shares during the period. Swedbank AB raised its holdings in Bristol-Myers Squibb by 0.9% in the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock worth $162,440,000 after acquiring an additional 28,427 shares during the period. KMG Fiduciary Partners LLC raised its holdings in Bristol-Myers Squibb by 2.0% in the 3rd quarter. KMG Fiduciary Partners LLC now owns 31,066 shares of the biopharmaceutical company's stock worth $1,607,000 after acquiring an additional 618 shares during the period. Moss Adams Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth $210,000. Finally, Blue Trust Inc. raised its holdings in Bristol-Myers Squibb by 50.0% in the 3rd quarter. Blue Trust Inc. now owns 25,501 shares of the biopharmaceutical company's stock worth $1,319,000 after acquiring an additional 8,498 shares during the period. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded up $0.82 on Thursday, reaching $55.80. The stock had a trading volume of 8,949,679 shares, compared to its average volume of 10,879,409. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The company has a market capitalization of $113.23 billion, a P/E ratio of -12.62, a price-to-earnings-growth ratio of 2.02 and a beta of 0.45. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a fifty day moving average price of $57.00 and a 200-day moving average price of $54.23.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.44%. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial raised their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Leerink Partners upgraded shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Bank of America restated a "neutral" rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald raised their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus target price of $57.86.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.